Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Abvc Biopharma (ABVC) over the last 11 years, with Q3 2025 value amounting to -$1.3 million.

  • Abvc Biopharma's Cash from Investing Activities fell 294072.95% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 283849.88%. This contributed to the annual value of -$360186.0 for FY2023, which is 7907.94% up from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Cash from Investing Activities is -$1.3 million, which was down 294072.95% from $44825.0 recorded in Q3 2024.
  • Abvc Biopharma's Cash from Investing Activities' 5-year high stood at $426846.0 during Q4 2021, with a 5-year trough of -$1.5 million in Q3 2022.
  • Its 5-year average for Cash from Investing Activities is -$306316.1, with a median of -$88254.0 in 2022.
  • In the last 5 years, Abvc Biopharma's Cash from Investing Activities skyrocketed by 29851.93% in 2021 and then plummeted by 294072.95% in 2025.
  • Over the past 5 years, Abvc Biopharma's Cash from Investing Activities (Quarter) stood at $426846.0 in 2021, then plummeted by 119.51% to -$83288.0 in 2022, then soared by 285.11% to $154173.0 in 2023, then tumbled by 70.93% to $44825.0 in 2024, then crashed by 2940.73% to -$1.3 million in 2025.
  • Its Cash from Investing Activities stands at -$1.3 million for Q3 2025, versus $44825.0 for Q3 2024 and $154173.0 for Q4 2023.